Philippe Calais - 14 Jun 2024 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNAZ	Stock Option (right to buy)	Award	$0	+70,000		$0.000000	70,000	14 Jun 2024	Common Stock	70,000	$1.20	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.